Want to see GB:AVCT full AI Analyst Report?
AVCT Stock Chart & Stats
64.50 p
0.40 p(0.62%)
At close: 4:00 PM EDT
64.50 p
0.40 p(0.62%)
Day’s Range― - ―
52-Week Range48.00 p - 92.00 p
Previous CloseN/A
Volume605.24K
Average Volume (3M)1.53M
Market Cap
£337.25M
Enterprise Value242.08 p
Total Cash (Recent Filing)£16.86M
Total Debt (Recent Filing)£14.92M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Apr 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume2,565,112
30 Day Avg. Volume1,531,756
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)£2.74M
Bulls Say, Bears Say
Bulls Say
Differentiated Pre|CISION Oncology PlatformThe pre|CISION platform has shown potentially meaningful mechanistic differentiation in preclinical testing, with higher tumor exposure and selectivity than comparator ADCs. If these advantages translate clinically, they could support stronger efficacy, targeted delivery, and partnering appeal.
Advancing Clinical PipelineOn-time AVA6103 dosing and progress toward an expansion dose for AVA6000 demonstrate continued clinical execution across the lead pipeline. Multiple advancing programs provide more than one route to future validation, licensing interest, and eventual commercial opportunity.
Improved Cost Control And Funded DevelopmentLower administrative spending and reduced operating cash outflows indicate some improvement in cost discipline while the company continues investing in its pipeline. Recent fundraising and cash on hand extend development capacity into early Q1 2027 without assuming partnering income.
Bears Say
Persistent Cash Burn And Financing DependenceSustained cash consumption means Avacta must continually balance clinical investment against available funding. The finite runway increases dependence on future fundraising or partnerships, which could constrain development choices and weaken financial flexibility if external capital is delayed.
Deep Losses And Unstable Revenue BaseThe current business has not yet demonstrated reliable commercial earnings power: revenue remains small and volatile, while losses persist and gross profit turned negative. This leaves future value heavily dependent on successful clinical development and eventual product commercialization.
Partnering Required For Pivotal AVA6000 DevelopmentMaking pivotal AVA6000 development conditional on securing a partner creates a material execution dependency beyond the company’s direct control. Delayed partnering could postpone larger trials, regulatory progress, and potential revenue, extending the period before the program can validate its commercial potential.
Avacta Group plc News
AVCT FAQ
What was Avacta Group PLC’s price range in the past 12 months?
Avacta Group PLC lowest share price was 48.00 p and its highest was 92.00 p in the past 12 months.
What is Avacta Group PLC’s market cap?
Avacta Group PLC’s market cap is £337.25M.
When is Avacta Group PLC’s upcoming earnings report date?
Avacta Group PLC’s upcoming earnings report date is Apr 22, 2027 which is in 204 days.
How were Avacta Group PLC’s earnings last quarter?
Avacta Group PLC released its earnings results on Sep 30, 2026. The company reported -0.042 p earnings per share for the quarter.
Is Avacta Group PLC overvalued?
According to Wall Street analysts Avacta Group PLC’s price is currently Overvalued.
Does Avacta Group PLC pay dividends?
Avacta Group PLC does not currently pay dividends.
What is Avacta Group PLC’s EPS estimate?
Avacta Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avacta Group PLC have?
Avacta Group PLC has 471,330,500 shares outstanding.
What happened to Avacta Group PLC’s price movement after its last earnings report?
Avacta Group PLC reported an EPS of -0.042 p in its last earnings report. Following the earnings report the stock price went down -2.959%.
Which hedge fund is a major shareholder of Avacta Group PLC?
Currently, no hedge funds are holding shares in GB:AVCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avacta Group plc Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Avacta Group PLC
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.
Technical Analysis
Nuformix Plc
―
PureTech Health
―
Scancell Holdings
―
4basebio UK Societas
―
Arecor Therapeutics PLC
―